June 23, 2016 14:19 ET
SYDNEY, AUSTRALIA--(Marketwired - June 23, 2016) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 10:00 am today (Australian Eastern Standard Time) in Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are attached.
For further information, please check our website (www.simavita.com).
Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ incontinence diagnostic tool kit which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.
SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect record and report incontinence events during a compulsory or recommended assessment period in residential aged care sites to develop an evidence-based incontinence care plan.
Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.
The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange not its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.
Simavita LimitedMs Peta Jurd+61 421 466 email@example.com
See all RSS Newsfeeds